Using CRISPR-Cas9 genome editing, we generated GBM cells lacking both IKKα and IKKβ (IKKαβ−/−) and verified that they were indeed deficient in downstream NF-κB signaling (Supplementary Fig. 4a, b). The gene discussed is IKBKB; the disease is glioblastoma.